Figures computed from official regulatory filings — .
Ownershipinsiders 29.94% · institutions 37.45%
In EUR · as of Oct 19, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for ONXEO only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, develops technology platforms dedicated to the targeted delivery of therapies. The company develops PlatON, a proprietary chemical platform for DNA decoy therapies, which generates new compounds and broadens its product portfolio; DecoyTAC, a mechanism of action of DNA decoy therapies coupled with targeted protein degradation; and V-body platform, a bispecific T-cell engagers, antibody" drug conjugates, and chimeric antigen receptors. The company was formerly known as Onxeo SA and changed its name to Valerio Therapeutics Société anonyme in June 2023. Valerio Therapeutics Société anonyme was incorporated in 1997 and is headquartered in Paris, France.
Market information source · Oct 19, 2026
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Financière de la Montagne SARL SARL | Award | $8.2M | Unusual size | AMF |
| Financière de la Montagne SARL SARL | Award | $1.8M | AMF |
| Financière de la Montagne SARL SARL | Other | $1.8M | AMF |
| INVUS | Sell | $8.2M | AMF |
| INVUS | Award | $5.4M | AMF |
| Financière de la Montagne SARL SARL | Award | $2.1M | AMF |
| Financière de la Montagne SARL SARL | Award | $3.3M | AMF |
| Financière de la Montagne SARL SARL | BuyD (derivative) | $13K | First in 12mo | AMF |
| Financière de la Montagne SARL SARL | Award | $3.6M | AMF |